Actionable news
0
All posts from Actionable news
Actionable news in VRX: VALEANT PHARMACEUTICALS INTERNATIONAL,

Valeant rallies 6.5% premarket after FDA approves Vyzulta drug

Valeant Pharmaceuticals International Inc. VRX, -7.29% jumped 6.5% in premarket action on Friday after the U.S. Food and Drug Administration late Thursday approved the company's Vyzulta drug. The drug, a treatment for open angle glaucoma, has been developed by Valeant's wholly-owned subsidiary Bausch + Lomb and France's Nicox SA COX, +26.06% Shares of Nicox soared 26% in Paris. "We expect to make this new advancement available for those who suffer with glaucoma before the end of the year," said Joseph C. Papa, Valeant's chairman and CEO, in a press release.


More